Zhenhua Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5092576/publications.pdf

Version: 2024-02-01

201674 302126 1,853 69 27 39 h-index citations g-index papers 74 74 74 2315 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical implications of high NQO1 expression in breast cancers. Journal of Experimental and Clinical Cancer Research, 2014, 33, 14.	8.6	130
2	Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment. Clinical Cancer Research, 2009, 15, 570-577.	7.0	98
3	NQO1 protein expression predicts poor prognosis of non-small cell lung cancers. BMC Cancer, 2015, 15, 207.	2.6	76
4	The Oncoprotein HBXIP Uses Two Pathways to Up-regulate \$100A4 in Promotion of Growth and Migration of Breast Cancer Cells. Journal of Biological Chemistry, 2012, 287, 30228-30239.	3.4	72
5	NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC Cancer, 2014, 14, 414.	2.6	65
6	High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma. BMC Cancer, 2015, 15, 244.	2.6	56
7	DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer, 2013, 13, 366.	2.6	55
8	Valproic acid targets HDAC1/2 and HDAC1/PTEN/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer. FEBS Journal, 2020, 287, 2118-2133.	4.7	50
9	High expression of ezrin predicts poor prognosis in uterine cervical cancer. BMC Cancer, 2013, 13, 520.	2.6	46
10	\hat{l}^2 -lapachone suppresses tumour progression by inhibiting epithelial-to-mesenchymal transition in NQO1-positive breast cancers. Scientific Reports, 2017, 7, 2681.	3.3	44
11	The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast. Journal of Experimental and Clinical Cancer Research, 2016, 35, 42.	8.6	43
12	DEK overexpression in uterine cervical cancers. Pathology International, 2008, 58, 378-382.	1.3	42
13	Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma. Diagnostic Pathology, 2012, 7, 135.	2.0	42
14	Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma. Experimental and Molecular Pathology, 2014, 96, 200-205.	2.1	42
15	Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis. Gene, 2018, 647, 306-311.	2.2	42
16	Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Experimental and Molecular Pathology, 2015, 98, 1-6.	2.1	39
17	DEK overexpression is correlated with the clinical features of breast cancer. Pathology International, 2012, 62, 176-181.	1.3	37
18	The NQO1/PKLR axis promotes lymph node metastasis and breast cancer progression by modulating glycolytic reprogramming. Cancer Letters, 2019, 453, 170-183.	7.2	36

#	Article	IF	CITATIONS
19	Ezrin contributes to cervical cancer progression through induction of epithelial-mesenchymal transition. Oncotarget, 2016, 7, 19631-19642.	1.8	36
20	Clinicopathological significance of DEK overexpression in serous ovarian tumors. Pathology International, 2009, 59, 443-447.	1.3	34
21	High expression of DEK predicts poor prognosis of gastric adenocarcinoma. Diagnostic Pathology, 2014, 9, 67.	2.0	34
22	Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC. Oncotarget, 2016, 7, 60169-60180.	1.8	34
23	Expression of Indian Hedgehog signaling molecules in breast cancer. Journal of Cancer Research and Clinical Oncology, 2009, 135, 235-240.	2.5	33
24	Ezrin promotes breast cancer progression by modulating AKT signals. British Journal of Cancer, 2019, 120, 703-713.	6.4	33
25	DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer. Oncotarget, 2017, 8, 98708-98722.	1.8	33
26	î"Np63 protein expression in uterine cervical and endometrial cancers. Journal of Cancer Research and Clinical Oncology, 2006, 132, 811-816.	2.5	29
27	Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer. BMC Cancer, 2014, 14, 191.	2.6	29
28	<p>Ezrin promotes pancreatic cancer cell proliferation and invasion through activating the Akt/mTOR pathway and inducing YAP translocation</p> . Cancer Management and Research, 2019, Volume 11, 6553-6566.	1.9	29
29	Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma. Gene, 2019, 696, 63-71.	2.2	29
30	Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast. BMC Cancer, 2016, 16, 681.	2.6	21
31	HBXIP over expression as an independent biomarker for cervical cancer. Experimental and Molecular Pathology, 2017, 102, 133-137.	2.1	20
32	Mortalin expression in pancreatic cancer and its clinical and prognostic significance. Human Pathology, 2017, 64, 171-178.	2.0	20
33	Mechanisms Underlying Cancer Growth and Apoptosis by DEK Overexpression in Colorectal Cancer. PLoS ONE, 2014, 9, e111260.	2.5	20
34	Paip1 affects breast cancer cell growth and represents a novel prognostic biomarker. Human Pathology, 2018, 73, 33-40.	2.0	19
35	Mortalin contributes to colorectal cancer by promoting proliferation and epithelial–mesenchymal transition. IUBMB Life, 2020, 72, 771-781.	3.4	19
36	Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma. Oncology Letters, 2017, 13, 2996-3002.	1.8	17

#	Article	IF	CITATIONS
37	Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma. Experimental and Molecular Pathology, 2014, 96, 54-60.	2.1	16
38	HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer. Journal of Ovarian Research, 2017, 10, 26.	3.0	16
39	Ezrin regulates skin fibroblast size/mechanical properties and YAP-dependent proliferation. Journal of Cell Communication and Signaling, 2018, 12, 549-560.	3.4	15
40	Paip1 predicts poor prognosis and promotes tumor progression through AKT/GSK-3Î ² pathway in lung adenocarcinoma. Human Pathology, 2019, 86, 233-242.	2.0	15
41	Ezrin promotes hepatocellular carcinoma progression by modulating glycolytic reprogramming. Cancer Science, 2020, 111, 4061-4074.	3.9	15
42	High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 5016-23.	0.5	15
43	<p>The prognostic value of Tiam1 correlates with its roles in epithelial–mesenchymal transition progression and angiogenesis in lung adenocarcinoma</p> . Cancer Management and Research, 2019, Volume 11, 1741-1752.	1.9	14
44	Lipid metabolism regulator human hydroxysteroid dehydrogenaseâ€ike 2 (HSDL2) modulates cervical cancer cell proliferation and metastasis. Journal of Cellular and Molecular Medicine, 2021, 25, 4846-4859.	3.6	14
45	Cordycepin Inhibits Cancer Cell Proliferation and Angiogenesis through a DEK Interaction via ERK Signaling in Cholangiocarcinoma. Journal of Pharmacology and Experimental Therapeutics, 2020, 373, 279-289.	2.5	13
46	Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China. Pathology International, 2008, 58, 643-647.	1.3	12
47	Sineoculis homeobox homolog 1 protein is associated with breast cancer progression and survival outcome. Experimental and Molecular Pathology, 2014, 97, 247-252.	2.1	12
48	Sineoculis homeobox homolog 1 protein as an independent biomarker for gastric adenocarcinoma. Experimental and Molecular Pathology, $2014,97,74-80.$	2.1	12
49	DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Oncology Reports, 2017, 37, 857-864.	2.6	12
50	Role of Paip1 on angiogenesis and invasion in pancreatic cancer. Experimental Cell Research, 2019, 376, 198-209.	2.6	12
51	Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder. Journal of Cancer Research and Clinical Oncology, 2011, 137, 49-54.	2.5	11
52	Clinical implication of Tiam1 overexpression in the prognosis of patients with serous ovarian carcinoma. Oncology Letters, 2016, 12, 3492-3498.	1.8	11
53	Upregulation of Tiam1 contributes to cervical cancer disease progression and indicates poor survival outcome. Human Pathology, 2018, 75, 179-188.	2.0	11
54	<p>Paip1 overexpression is involved in the progression of gastric cancer and predicts shorter survival of diagnosed patients</p> . OncoTargets and Therapy, 2019, Volume 12, 6565-6576.	2.0	11

#	Article	IF	Citations
55	Paip1 Indicated Poor Prognosis in Cervical Cancer and Promoted Cervical Carcinogenesis. Cancer Research and Treatment, 2019, 51, 1653-1665.	3.0	11
56	Overexpression of sineoculis homeobox homolog 1 predicts poor prognosis of hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2014, 7, 3018-27.	0.5	11
57	LETM1 overexpression is correlated with the clinical features and survival outcome of breast cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 12893-900.	0.5	11
58	The molecular mechanism of baicalein repressing progression of gastric cancer mediating miR-7/FAK/AKT signaling pathway. Phytomedicine, 2022, 100, 154046.	5.3	11
59	SPOCK1 promotes metastasis in pancreatic cancer via NF-κB-dependent epithelial-mesenchymal transition by interacting with llºB-α. Cellular Oncology (Dordrecht), 2022, 45, 69-84.	4.4	11
60	Significant association of PKM2 and NQO1 proteins with poor prognosis in breast cancer. Pathology Research and Practice, 2020, 216, 153173.	2.3	10
61	SPOCK1/SIX1axis promotes breast cancer progression by activating AKT/mTOR signaling. Aging, 2021, 13, 1032-1050.	3.1	10
62	High Expression of Leucine Zipper-EF-Hand Containing Transmembrane Protein 1 Predicts Poor Prognosis in Head and Neck Squamous Cell Carcinoma. BioMed Research International, 2014, 2014, 1-8.	1.9	9
63	Cellular adjustment of gastric cancer for hepatic metastasis in successive orthotopic implantation model. Cancer Biology and Therapy, 2006, 5, 1313-1319.	3.4	7
64	<p>Ectopic expression of HSDL2 is related to cell proliferation and prognosis in breast cancer</p> . Cancer Management and Research, 2019, Volume 11, 6531-6542.	1.9	6
65	Ezrin as a prognostic indicator regulates colon adenocarinoma progression through glycolysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 710-720.	2.8	5
66	miR-21-5p/Tiam1-mediated glycolysis reprogramming drives breast cancer progression via enhancing PFKL stabilization. Carcinogenesis, 2022, 43, 705-715.	2.8	4
67	Commentary on statistical mechanical models of cancer. Physica A: Statistical Mechanics and Its Applications, 2021, 572, 125877.	2.6	1
68	The Significance of SIX1 as a Prognostic Biomarker for Survival Outcome in Various Cancer Patients: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 622331.	2.8	1
69	CD44 enhances adriamycin resistance in chronic myelogenous leukaemia cells K562. International Journal of Laboratory Hematology, 2021, 43, 983-989.	1.3	0